摘要：新型口服磷酸二酯酶4B（PDE4B）抑制剂nerandomilast在进展性肺纤维化（PPF）患者中开展的关键Ⅲ期临床试验FIBRONEER-ILD达到主要研究终点，于今日重磅发表于国际顶尖医学期刊《新英格兰医学杂志》（NEJM）。
导语：新型口服磷酸二酯酶4B（PDE4B）抑制剂nerandomilast在进展性肺纤维化（PPF）患者中开展的关键Ⅲ期临床试验FIBRONEER-ILD达到主要研究终点，于今日重磅发表于国际顶尖医学期刊《新英格兰医学杂志》（NEJM）。
结果显示，第52周时，与安慰剂组相比，Nerandomilast两种剂量组均显著减少了PPF患者用力肺活量（FVC）的下降，具有可接受的安全性和耐受性，且可能有望降低PPF患者死亡风险
。参考文献
1. Maher TM et al. Nerandomilast in Patients with Progressive Pulmonary Fibrosis. N Engl J Med 2025.
2. Maher TM. Interstitial Lung Disease: A Review. JAMA. 2024 May 21;331(19):1655-1665.1.
3. Keith R, et al. Potential of phosphodiesterase 4B inhibition in the treatment of progressive pulmonary fibrosis. Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666241309795.
4. Huang H, Wang Q, Xu Z. Advances in the identification and management of progressive pulmonary fibrosis: perspective from Chinese experts. Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241288417.
5. Lamb YN. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases. Drugs. 2021 Apr;81(5):575-586.
6. Cottin V, et al. Evidence from recent clinical trials in fibrotic interstitial lung diseases. Curr Opin Pulm Med. 2024 Sep 1;30(5):484-493.
7. Maher TM, et al. Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD). BMJ Open Respir Res. 2023 Sep;10(1):e001580.
8. Phase 3 Trials of Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis (FIBRONEER-IPF) and Progressive Pulmonary Fibrosis (FIBRONEER-ILD). 2025 ATS.
9. Boehringer's nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study. Accessed January 2025. Available at: https://www.boehringer-ingelheim.com/us/topline-results-boehringers-phase-iii-ipf-study.
10. Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis. Accessed february 2025. Available at: https://www.boehringer-ingelheim.com/us/topline-results-boehringers-phase-iii-ild-study.
有效期至：5/20/2026
仅供相关医药专业人士进行医学科学交流
本视频/资讯/文章的内容不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。来源：医脉通呼吸科一点号1
